NIH Consensus Development Conference:
Management of Hepatitis B
October 20-22, 2008CME Information
Description
The NIH Consensus Development Program is convening a consensus development conference to assess the available evidence on the management of hepatitis B. The conference statement will be prepared by an independent panel on the basis of a systematic literature review, expert presentations, and audience commentary. Widely distributed to the biomedical community and covered by the news media, the statement will help inform both healthcare providers and the general public, and shape the research agenda for this complex disease.
Who Should Attend
It is important that all key stakeholders be represented, as attendees will have the opportunity to participate in engaging discussions that will influence the panel’s statement. This conference is intended for physicians and other health practitioners, healthcare system professionals, health policy specialists, public health experts, researchers, and interested members of the public.
Objectives
At the end of this activity, participants will be able to:
Recognize the current burden of hepatitis B.
Describe the natural history of hepatitis B.
Discuss the benefits and risks of the current therapeutic options for hepatitis B.
Identify which persons with hepatitis B should be treated.
Use appropriate measures to monitor therapy and assess outcomes.
Explain the greatest needs and opportunities for future research on hepatitis B.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Johns Hopkins University School of Medicine and the National Institutes of Health. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 13.00 AMA PRA Category 1 Credit(s)tm . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Speaker and Provider Disclosure
It is the policy of The Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine Office of Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Contact Consensus Program | Privacy Notice | Disclaimer | Accessibility | Contact NIH